Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-label, Multi-Center Study to Evaluate the long term Safety of nemolizumab in Japanese Atopic Dermatitis Patients with moderate to severe pruritus

Next Previous
Trial Profile

A Phase III, Open-label, Multi-Center Study to Evaluate the long term Safety of nemolizumab in Japanese Atopic Dermatitis Patients with moderate to severe pruritus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemolizumab (Primary)
  • Indications Atopic dermatitis; Pruritus
  • Focus Adverse reactions; Registrational
  • Acronyms Study-JP02
  • Sponsors Maruho

Most Recent Events

  • 22 Jun 2022 Status changed from active, no longer recruiting to completed.
  • 28 Mar 2022 According to a Maruho media release, the company has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for "Mitchga Subcutaneous Injection 60mg Syringes" for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective) in Japan.
  • 02 Nov 2021 Results published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top